semaglutide + bpc-157 2.5 mg + 500 mcg/ml Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review Sema (GLP-1) / BPC-157 -

Mild elevations in C-reactive protein have been reported in PTLD (106), however moderate to severe elevations in the erythrocyte sedimentation rate or C-reactive protein are distinctly unusual and should prompt evaluation of another infectious, neoplastic, or autoimmune condition, such as polymyalgia rheumatica

While BPC-157 can be injected or orally consumed, the latter route may be associated with more targeted effects on the GI tract

As enthusiastic as he is about the potential of peptides, he told me, people should not be taking them until theyre fully tested

References: [1] Chung-Hsun Chang, Wen-Chung Tsai, Ya-Hui Hsu, and Jong-Hwei Su Pang (2014) Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts Molecules, 2014 Nov, Volume 19 (Issue 11), Pages 1906619077

Toba T, Nakamura T, Shimizu Y, et al

Current research is exploring the use of BPC-157 in experimental settings for conditions such as: Musculoskeletal injuries (tendons, ligaments, muscles) Gut lining repair and inflammatory bowel conditions Post-operative recovery Inflammatory-related disorders It is important to note that evidence in humans is still emerging, and use should always be discussed with a qualified clinician who can evaluate safety, dosage, and appropriateness on a case-by-case basis